# Multiome QC & Hypothesis Agent report (private)

*Model: `claude-opus-5` · total cost: $42.3547*

## 1. Dataset & fixed-core summary

**Data source:** private multi-cell-line multiome data. Loading strategy was determined by the agent itself from real file structure, not pre-specified: it decided `separate_per_modality_files` -- "No file has a feature_types column mixing "Gene Expression" and "Peaks"; instead the modalities are split across files sharing the same 5,814 obs: two gene-expression matrices (19,129 and 3,697 vars, with gene-specific var columns like mt/ribo/hb/highly_variable/binomial_deviance) and one chromatin-accessibility matrix (1,578,279 vars with only an index column, plus ATAC-specific obs fields such as frip, n_fragment, tsse, frac_mito)."

5814 cells pooled from 8 distinct cell lines, 19129 genes, 133743 ATAC peaks (after feature filtering). RNA: 14 Leiden clusters, median 4258 genes/cell, 9296 UMIs/cell, 7.0% mito, 10.6% doublets (scrublet-based call). ATAC: 10 Leiden clusters, median 8484 fragments/cell, median FRiP 0.62, median TSS enrichment 14.6. RNA-ATAC cross-modal cluster agreement (ARI): 0.725. Recovery of true (genotype-confirmed) cell-line identity from unsupervised clustering (ARI vs. ground truth): RNA=0.767, ATAC=0.906. chromVAR-style motif accessibility deviations are available for this dataset -- use the tf_motif_correlation tool to check a specific transcription factor's expression against its own motif's accessibility.

---

## 2. Gene activity, chromVAR motif deviations, and cross-modal validation

Gene activity scores and chromVAR-style motif deviations are part of the fixed-core pipeline (computed once, cached, reused here). The table below is the textbook ArchR/Signac cross-modal cell-type-call validation: for each gene checked while investigating this dataset (identity discovery, known-biology checklist, novel-finding review), is it a significant RNA marker of some cluster, AND does its independently-computed ATAC gene-activity confirm elevated accessibility in that cluster's real cross-modal partner?

| Gene | RNA marker of cluster | Matched ATAC cluster | Gene-activity confirms |
|---|---|---|---|
| ESR1 | 4 | 4 | True |
| GREB1 | 4 | 4 | True |
| GRHL2 | 4 | 4 | True |
| PGR | 4 | 4 | True |
| PRLR | 4 | 4 | True |
| TRPS1 | 4 | 4 | True |

6/6 checked markers cross-validate between modalities. Per CLAUDE.md's design principle, discordance here is expected, not a bug -- gene activity is a noisier, indirect accessibility proxy, and RNA-ATAC agreement is not assumed to be perfect.

---

## 3. Known-biology checklist (literature RAG, identity determined by the agent)

**Identity determination:** **This is not a tissue sample — it's a pooled panel of 8 human cancer cell lines**, and the dataset's own `.obs` says so directly. Both the RNA and ATAC modalities carry a `cell_line_name` field plus DepMap Model IDs (`ACH-XXXXXX`), with a companion QC flag (`may_have_wrong_cell_line_label_*` = "no" for all 5,814 cells):

| Cell line | DepMap ID | Cells (ATAC label) | Lineage (from `atac_lineage`) |
|---|---|---|---|
| NCI-H838 | ACH-000416 | 1,626 | Lung |
| HCC-44 | ACH-000667 | 817 | Lung |
| SJSA1 | ACH-000748 | 773 | Bone |
| **T-47D** | **ACH-000147** | **697** | **Breast** |
| OVTOKO | ACH-000663 | 627 | Ovary/Fallopian tube |
| LN-229 | ACH-000595 | 579 | CNS/Brain |
| YKG1 | ACH-000570 | 531 | CNS/Brain |
| A-673 | ACH-000052 | 164 | Bone |...

Each item below required the agent to: search PubMed, fetch and actually read a real abstract (not just a title), and verify with a real tool call that the gene/motif is usable in this dataset before recording it.

### RNA markers

- **ESR1**: ESR1 (ERα) is expressed in T-47D, an ERα-positive luminal breast cancer line; here ESR1 is a top RNA marker of the T-47D cluster (RNA cluster 4, logFC 5.01, padj 8.3e-245) with ATAC gene-activity confirmation. (PMID 27888136, *The Journal of steroid biochemistry and molecular biology*, 2017; data-presence verified: True)
- **PGR**: T-47D is progesterone-receptor (PGR)-positive; here PGR is a top RNA marker of the T-47D cluster (RNA cluster 4, logFC 5.32, padj 6.3e-242) and is cross-modally confirmed by ATAC gene activity. (PMID 35617163, *PloS one*, 2022; data-presence verified: True)
- **GREB1**: GREB1, a direct ER-regulated early-response gene, correlates with ER-positive phenotype across breast cancer cell lines and so should be enriched in T-47D; here GREB1 is a top RNA marker of the T-47D cluster (RNA cluster 4, logFC 4.85, padj 2.5e-219) with ATAC gene-activity confirmation. (PMID 11103799, *Cancer research*, 2000; data-presence verified: True)

### Motifs

- **MA0148.5.FOXA1**: The FOXA1 forkhead motif should show elevated chromatin accessibility in T-47D, since FOXA1 is a pioneer factor that exclusively initiates chromatin opening at its own genomic binding sites and is essential for growth of breast cancers; the FOXA1 motif (MA0148.5) is present in this dataset's chromVAR deviations. (PMID 41808995, *bioRxiv : the preprint server for biology*, 2026; data-presence verified: True)
- **MA0037.5.Gata3**: The GATA3 motif should show elevated accessibility in luminal ER+ cells such as T-47D: GATA3 is a luminal-defining transcription factor whose motif accessibility marks the luminal chromatin landscape and is lost upon luminal-to-basal reprogramming; the GATA3 motif (MA0037.5) is present in this dataset's chromVAR deviations. (PMID 35021081, *Cell reports*, 2022; data-presence verified: True)
- **MA0112.4.ESR1**: Estrogen response elements (the ESR1 motif) should be in accessible chromatin in T-47D: in T-47D cells specifically, chromatin accessibility at EREs is predictive of ER genomic binding and regulatory activity (with FOXA1 and GATA3 as the T-47D-specific predictive TFs); the ESR1 motif (MA0112.4) is present in this dataset's chromVAR deviations. (PMID 42469015, *Genome research*, 2026; data-presence verified: True)

### TF-expression-tracks-motif-accessibility

- **FOXA1**: FOXA1 abundance should track accessibility at its own motif in breast cancer cells: acute pharmacological degradation of FOXA1 shows it exclusively initiates chromatin opening at its own genomic binding sites, so FOXA1 levels causally set FOXA1-motif accessibility. In this dataset FOXA1 RNA vs FOXA1 motif (MA0148.5) chromVAR deviation gives Spearman rho = 0.108, p = 2.0e-16. (PMID 41808995, *bioRxiv : the preprint server for biology*, 2026; data-presence verified: True)
- **NR2F2**: NR2F2 expression level should track accessibility at NR2F2-bound/motif-containing ERalpha regulatory elements in ER+ breast cancer: perturbation of NR2F2 expression decreases ERalpha DNA binding and chromatin opening, and NR2F2 co-binds with FOXA1/GATA3 at 85% of ERalpha sites. In this dataset NR2F2 RNA vs its motif (MA1111.2) gives Spearman rho = -0.018, p = 0.18 (not significant). (PMID 31588232, *Theranostics*, 2019; data-presence verified: True)
- **GATA3**: GATA3, a known pioneer factor in ER+ breast cancer that co-binds FOXA1/NR2F2 and renders ERE-containing sites pre-accessible, should have its expression track its own motif's accessibility. In this dataset GATA3 RNA vs GATA3 motif (MA0037.5) gives Spearman rho = -0.079, p = 2.0e-09 -- i.e. weakly negative rather than positive, so the expected tracking is not observed. (PMID 31588232, *Theranostics*, 2019; data-presence verified: True)


---

## 4. Fault-injection eval (compared across models)

| Model | Faults detected | Correct diagnosis | False alarms | Cost/run |
|---|---|---|---|---|
| claude-haiku-4-5 | 3/3 | 3/3 | 0/1 | $0.01196 |
| claude-sonnet-5 | 3/3 | 3/3 | 1/1 | $0.18072 |
| claude-opus-5 | 3/3 | 3/3 | 1/1 | $1.74888 |
| claude-fable-5 | 3/3 | 3/3 | 1/1 | $1.41175 |

"Faults detected"/"Correct diagnosis" use heuristic free-text classifiers on each model's open-ended answer, not exact ground-truth string matching.

### Per-scenario answers (claude-opus-5)

**clean_control** (Unmodified private multi-cell-line data.)

## Answer

**No, this is not clean.** The core QC metrics are fine, but there's a specific, serious problem in the **RNA-side cell-line label assignment**, and a QC flag that is silently failing to catch it.

### What the sample is (discovered from the data's own metadata)
`check_for_identity_columns` returned real named fields: 8 pooled cancer cell lines — **NCI-H838** (1626), **HCC-44** (817), **SJSA1** (773), **T-47D** (697), **OVTOKO** (627), **LN-229** (579), **YKG1** (531), **A-673** (164) — spanning Lung, CNS/Brain, Bone, Breast, Ovary. `check_for_condition_groups` found no treatment axis (`is_control_only: true`), so this is control-only; don't split it by condition.

### What looks fine
- ATAC is genuinely good: median 8484 fragments/cell, **FRiP 0.62**, **TSS enrichment 14.6** — all well above typical pass thresholds.
- RNA depth is healthy: median 4258 genes / 9296 UMIs per cell.
- Batch structure is not obviously driving things: 26 sequencing samples, largest only 567 cells, internal mito IQR 1.79.
- Identity is recovered by unsupervised clustering (ARI vs. genotype truth: RNA 0.767, **ATAC 0.906**), and cross-modal cluster agreement is reasonable (ARI 0.725).

### The specific problem: RNA genotype labels are badly degraded for a subset of lines
The two identity columns disagree in a way that is not random noise:

| Line | `atac_label` cells | `rna_label` cells |
|---|---|---|
| SJSA1 (ACH-000748) | 773 | **77** |
| YKG1 (ACH-000570) | 531 | **33** |
| T-47D (ACH-000147) | 697 | **371** |

`atac_label` is a clean 8-category field. `rna_label` fragments those same 5814 cells across **~68 different DepMap IDs**, with a long tail of singletons, plus one substantial off-panel call (ACH-000171, 98 cells) that isn't one of the 8 lines at all. Correspondingly, `atac.rna_lineage` assigns cells to lineages that don't exist in this pool — Kidney (118), Bladder (40), Skin (27), "Other" (427) — while `atac.atac_lineage` contains exactly the 5 real lineages and nothing else.

**This is not the expected kind of RNA–ATAC discordance.** Weak per-gene RNA↔ATAC correlation is normal and biological; a *sample-identity assignment* disagreeing by 10-fold on which line a cell came from is a technical failure, because both labels are supposed to be reading the same underlying genotype. The asymmetry (ATAC clean, RNA scattered) points to the RNA-side genotype demultiplexing being underpowered or confounded — consistent with the elevated **10.6% doublet rate** and **7.0% median mito** (ambient/cross-contaminating RNA makes SNP-based RNA demux drift toward spurious reference lines).

I checked that the cells themselves are real and correctly grouped: `cross_modal_marker_check` on **MDM2** shows it is a significant RNA marker of RNA cluster 1 with independent ATAC gene-activity confirmation in the matched ATAC cluster 1 — i.e. the MDM2-amplified SJSA1 population is present and coherent in *both* modalities, even though only 77 of its ~773 cells got an RNA-side SJSA1 label. So the problem is in the labeling layer, not in the cells or the clustering.

### Second problem: the built-in mislabel flag is uninformative
`may_have_wrong_cell_line_label_based_on_rna_cluster` and `..._based_on_atac` both return **"no" for all 5814 cells** — zero flagged. Given the ~68-way RNA label scatter above, this flag is clearly not functioning as a QC filter and should not be trusted to gate anything.

### Minor caveats
- **A-673** has only 164 cells and 74,434 peaks vs ~180,000 for the other lines — underpowered; treat any A-673-specific claim cautiously.
- 14 RNA clusters for 8 lines means some lines are splitting (cell cycle / subpopulation), which is normal but worth knowing before interpreting cluster counts as line counts.

### Recommendation
Use **`atac_label` / `cell_line_name`** as the identity ground truth for downstream work, not `rna_label`. Re-run RNA-side demultiplexing with ambient-RNA correction and doublet removal before trusting it, and don't rely on the `may_have_wrong_cell_line_label_*` flags.

---

## Evidence

- **8 named cell lines, no condition axis** — `check_for_identity_columns` (`cell_line_name`: NCI-H838 1626, HCC-44 817, SJSA1 773, T-47D 697, OVTOKO 627, LN-229 579, YKG1 531, A-673 164); `check_for_condition_groups` (`is_control_only: true`). **Confidence: high** (real metadata fields, not inference).
- **Core QC values** (5814 cells; RNA 4258 genes / 9296 UMIs / 7.0% mito / 10.6% doublets; ATAC 8484 fragments / FRiP 0.62 / TSS 14.6; ARI 0.725; identity-recovery ARI RNA 0.767 vs ATAC 0.906; 26 samples, largest 567 cells, mito IQR 1.79) — `get_qc_summary`. **Confidence: high.**
- **RNA-vs-ATAC label discordance** (SJSA1 773→77, YKG1 531→33, T-47D 697→371; ~68 RNA-label categories; off-panel ACH-000171 at 98 cells; `rna_lineage` containing Kidney/Bladder/Skin/Other) — `check_for_identity_columns`. **Confidence: high** that the discrepancy exists; **medium** on my attribution of the cause to ambient RNA + doublets degrading RNA-side genotype demux (the QC numbers are consistent with it, but no tool here directly tested ambient contamination).
- **SJSA1 population is real and cross-modally coherent** — `cross_modal_marker_check("MDM2")`: `is_rna_marker: true` (RNA cluster 1), `gene_activity_confirms: true` (matched ATAC cluster 1). **Confidence: high.**
- **SJSA-1 carries MDM2 amplification**, supporting MDM2 as the identifying marker for that cluster — PMID **33952867** (abstract read; describes SJSA-1 as "human osteosarcoma cell line... which has wild-type p53 and amplification of the Mdm2 gene"). **Confidence: high.**
- **Mislabel flags all "no"** for 5814/5814 cells — `check_for_identity_columns`. **Confidence: high** that the flag is uninformative here.
- **General point that ambient RNA/doublets impair SNP-based RNA demultiplexing more than ATAC** — background knowledge, not produced by any tool in this conversation. **Confidence: medium.**

**cell_line_label_swap** (1744/5814 cells' cell-line label reassigned to a different real cell line.)

## Answer

**Per-cell QC is clean; the labels are not.** There is one specific, real problem: the RNA-side cell-line assignment is unreliable and badly disagrees with the ATAC-side assignment, and the dataset's own "wrong-label" flag is degenerate and hides it.

### What the sample is (found in the data, not assumed)
`check_for_identity_columns` returned a real `cell_line_name` field: 8 pooled lines — NCI-H838 (1626), HCC-44 (817), SJSA1 (773), T-47D (697), OVTOKO (627), LN-229 (579), YKG1 (531), A-673 (164) — spanning lung, bone, breast, ovary and CNS/brain lineages, with matching DepMap IDs. `check_for_condition_groups` found **no** treatment axis (`is_control_only: true`); there is a 3-level batch field (`Depmap`: b2=3186, b3=1324, b1=1304), all adequately sized.

### What looks fine
- **ATAC is strong**: median 8484 fragments/cell, FRiP 0.62, TSS enrichment 14.6 — all comfortably above standard thresholds (background knowledge for thresholds; numbers from `get_qc_summary`). **High confidence.**
- **RNA depth and mito**: 4258 genes, 9296 UMIs, 7.0% mito median — acceptable for cancer lines. **High confidence.**
- **Clustering is biologically real**: cluster 1 is MDM2/COL1A1/COL11A1-high (consistent with the MDM2-amplified osteosarcoma line SJSA1 — amplification status is background knowledge); cluster 5 is ESR1/PGR/GREB1/TRPS1/GRHL2-high (ER+ breast, i.e. T-47D). Both are cross-modally corroborated: `cross_modal_marker_check` confirms ESR1 (RNA cluster 4 → ATAC cluster 4) and MDM2 (RNA 1 → ATAC 1) with gene-activity agreement. Cross-modal cluster ARI is 0.725. **High confidence.**

### The problem
1. **RNA-side genotype labels are corrupted.** `atac_label` is a clean 8-way split exactly matching `cell_line_name`. `rna_label` fragments into ~70 categories: SJSA1 (ACH-000748) gets 773 cells by ATAC but only **77** by RNA; YKG1 (ACH-000570) **531 vs 33**; T-47D (ACH-000147) **697 vs 371**. On top of that, ~60 DepMap IDs *not in the 8-line panel* appear with 1–17 cells each (plus ACH-000171 with 98 cells, absent from the ATAC labels entirely). **High confidence** — straight from `check_for_identity_columns`.
2. **The headline "identity recovery" number is therefore misleading, not a clustering failure.** `get_qc_summary` reports ARI vs ground truth of RNA=0.363, ATAC=0.414 — which would normally scream "clustering can't separate 8 distinct lines." But the clusters *are* line-specific (point 3 above), and over-clustering (14 RNA / 10 ATAC clusters for 8 lines) plus a noisy reference label both depress ARI. My read: the low ARI is driven mainly by the bad reference label, secondarily by over-clustering. **Medium confidence** — this is my interpretation of the tool numbers, not something a tool asserted.
3. **The built-in QC flag is degenerate.** `may_have_wrong_cell_line_label_based_on_rna_cluster` and `may_have_wrong_cell_line_label_based_on_atac` are both `"no"` for all **5814/5814** cells. A zero-variance flag provides no filtering and directly contradicts the RNA/ATAC label discordance above. Do not rely on it. **High confidence.**
4. **Contributing factor, likely:** 10.6% scrublet doublets is on the high side, and in a pooled multi-line design cross-line doublets produce exactly this signature — ambiguous genotype demultiplexing that scatters cells onto spurious third lines. **Medium confidence** (mechanism is background knowledge; the 10.6% is from `get_qc_summary`).
5. **Minor oddity worth a look:** median 4258 genes on median 9296 UMIs (~2.2 UMIs per detected gene) is higher library complexity than typical 10x data, which can indicate the two medians were computed on differently processed matrices. **Low confidence** — flagging for verification, not asserting a defect.

### Practical recommendation
Use `cell_line_name` / `atac_label` as the identity ground truth; treat `rna_label` as unusable for per-cell assignment. Re-derive the identity-recovery ARI against the ATAC/name label, and consider a stricter doublet filter before any per-line differential analysis.

### Evidence
- `get_qc_summary`: 5814 cells / 8 lines; RNA 4258 genes, 9296 UMIs, 7.0% mito, 10.6% doublets; ATAC 8484 fragments, FRiP 0.62, TSS 14.6; 14 RNA / 10 ATAC clusters; cross-modal ARI 0.725; ground-truth ARI RNA 0.363 / ATAC 0.414 — **high confidence** in the numbers.
- `check_for_identity_columns`: 8-line `cell_line_name`; `atac_label` clean vs `rna_label` fragmented (SJSA1 773→77, YKG1 531→33); constant "no" flag columns — **high confidence**.
- `check_for_condition_groups` / `condition_group_qc`: no treatment axis; 3 batches, none underpowered — **high confidence**.
- `top_cluster_markers` (clusters 0/1/5) + `cross_modal_marker_check` (ESR1, MDM2 both confirmed in both modalities) — **high confidence** that clusters track cell lines.
- SJSA-1 MDM2 amplification and T-47D ER/PR positivity: **background knowledge**, not a tool result.

**mixed_samples** (282 cells from a second sequencing library (anonymized 'A') relabeled to appear part of a different sample ('B').)

## Answer

**Not clean.** The ATAC side is excellent; the RNA side has a specific, identifiable defect: **the RNA-based cell-line genotype assignment is unreliable and internally inconsistent, and the dataset's own mislabeling flags fail to catch it.**

### What this dataset is (found in its own metadata)
5,814 cells pooled from **8 cancer cell lines**: NCI-H838 and HCC-44 (lung), SJSA1 (osteosarcoma), A-673 (Ewing sarcoma), T-47D (breast), OVTOKO (ovarian), LN-229 and YKG1 (CNS/glioma). No drug/treatment axis — `check_for_condition_groups` returned `is_control_only: true`, so this is a control-only pool.

### What looks wrong

**1. RNA genotype labels contradict ATAC genotype labels, and contradict themselves (confidence: high that it's real, medium on mechanism).**
`atac_label` is clean: exactly 8 lines, identical values stored in both the RNA and ATAC objects, and it is exactly what `cell_line_name` is derived from. `rna_label` is not:
- It has a long tail of ~60 extra cell lines at 1–2 cells each.
- For two lines it disagrees massively with the ATAC call: SJSA1 (ACH-000748) is 773 cells by ATAC but only **77** by RNA; YKG1 (ACH-000570) is 531 by ATAC but only **33** by RNA.
- Worse, the *same-named* `rna_label` column holds **different values in the two modality objects** (SJSA1: 77 in `rna.rna_label` vs 653 in `atac.rna_label`; YKG1: 33 vs 423). Two copies of one annotation that don't match means at least one is stale or mis-joined.

Practical consequence: every identity in `cell_line_name` rests on the ATAC call alone. The RNA modality provides no working independent confirmation for SJSA1 and YKG1 in particular.

**2. The built-in QC flags are non-functional (confidence: high).**
`may_have_wrong_cell_line_label_based_on_rna_cluster` and `..._based_on_atac` are `"no"` for **5,814 / 5,814 cells** — zero flagged, despite point 1. Don't rely on these columns; they assert cleanliness they haven't demonstrated.

**3. Doublets called but apparently not removed (confidence: medium).**
Scrublet rate is 10.6%, and the cell count is unchanged at 5,814. In an 8-line pool, inter-line doublets are the most parsimonious explanation for the ~60-line singleton tail in `rna_label`.

**4. RNA over-clustering (confidence: high).**
14 RNA Leiden clusters for 8 lines, and RNA recovers true identity worse than ATAC (ARI 0.767 vs **0.906**). I checked directly: RNA clusters 12 and 13 share markers (TGFBR3, DENND5B, MCTP2, CARD18) at modest logFC ≈1.3–2.8, i.e. they are sub-splits of one line (MUC16 in cluster 12 points to the ovarian line), whereas cluster 11 is a genuinely distinct neural-program cluster (DCC logFC 7.5, NELL2 7.0, NTNG1 5.5). So the extra clusters are resolution artifacts, not extra identities.

**5. Severe class imbalance:** A-673 has only 164 cells (2.8% of the pool) — too few to anchor confident line-specific claims.

**6. Median 7.0% mitochondrial reads** is high for a nuclei-based multiome assay, where nuclei should carry little mitochondrial RNA (*background knowledge*, not a tool output). Worth a look, though the largest sample's internal mito IQR of 1.84 argues the elevation is uniform, not a few dying cells.

### What is *not* wrong
- **The modalities are correctly paired.** I tested this rather than assumed it: `cross_modal_marker_check` on ESR1 returned RNA cluster 4 ↔ ATAC cluster 4 with gene activity independently confirming. So the label discordance in point 1 is an annotation problem, **not** global barcode scrambling. (confidence: medium-high — one gene, but a decisive one for the breast line.)
- **ATAC quality is genuinely strong:** median 8,484 fragments/cell, FRiP 0.62, TSS enrichment 14.6 — all comfortably above standard thresholds (*thresholds from background knowledge*; the values from `get_qc_summary`).
- GFAP and NKX2-1 returned `is_rna_marker: false`. That is *not* a red flag — these are differentiation markers frequently silenced in established glioma and lung lines, and absence of a marker isn't evidence of a QC problem.

### Recommendation
Treat `cell_line_name` / `atac_label` as the identity of record, ignore `rna_label` and both `may_have_wrong_cell_line_label` columns, drop or explicitly gate the scrublet-flagged 10.6%, and lower the RNA clustering resolution to ~8 before doing anything that assumes clusters equal lines.

---

### Evidence
| Claim | Source | Confidence |
|---|---|---|
| 8 lines, names, per-line cell counts; control-only | `check_for_identity_columns`, `check_for_condition_groups` | High |
| RNA vs ATAC label discordance (SJSA1 773/77, YKG1 531/33) and `rna_label` differing between objects (77 vs 653; 33 vs 423) | `check_for_identity_columns` | High (observation); Medium (cause = ambiguous RNA SNP calls + doublets) |
| Mislabel flags "no" for 5,814/5,814 | `check_for_identity_columns` | High |
| ARI: RNA 0.767 vs ATAC 0.906; 14 vs 10 clusters; 10.6% doublets; mito 7.0%; FRiP 0.62; TSS 14.6; 8,484 fragments | `get_qc_summary` | High |
| Clusters 12/13 are sub-splits (shared markers, logFC 1.3–2.8); cluster 11 genuinely distinct (DCC logFC 7.5) | `top_cluster_markers` on 11, 12, 13 | High |
| Modalities correctly paired | `cross_modal_marker_check` (ESR1: RNA c4 ↔ ATAC c4, confirmed) | Medium-high |
| 7% mito is high for a nuclei assay; FRiP/TSS thresholds | Background knowledge, not a tool result | Medium |

**shuffled_rna_atac_pairing** (2907/5814 cells have their ATAC profile swapped with another cell's.)

## Verdict

The assay chemistry looks good; the **annotation/integration layer does not**. There are two specific things I'd call wrong, and one thing to be careful with.

### What's fine
- **RNA depth:** median 4,258 genes and 9,296 UMIs/cell; median mito 7.0% (a bit high for cell lines but not alarming; the largest sample's internal mito IQR is only 1.79, so no single sample is driving it).
- **ATAC:** median 8,484 fragments/cell, FRiP 0.62, TSS enrichment 14.6 — all comfortably above standard thresholds.
- **Composition:** 5,814 cells, 8 genotype-confirmed lines, read straight from the dataset's own metadata: NCI-H838 (1,626), HCC-44 (817), SJSA1 (773), T-47D (697), OVTOKO (627), LN-229 (579), YKG1 (531), A-673 (164). Lineages: lung, bone, CNS/brain, breast, ovary. No drug/condition axis exists (`check_for_condition_groups`: control-only) — don't analyze one.
- **Pairing is not globally scrambled:** ESR1 is an RNA marker of RNA cluster 4 and ATAC gene activity independently confirms it in the matched ATAC cluster 4; same for MDM2 (RNA cluster 1 → ATAC cluster 1), which fits an MDM2-amplified osteosarcoma line (background knowledge).

### Problem 1 — the RNA-side cell-line label column is corrupted/unreliable (high confidence)
- `atac_label` is a clean 8-way partition matching `cell_line_name` exactly. `rna_label` is not: it carries a long tail of ~60 extra DepMap IDs with 1–17 cells each (spurious assignments).
- Worse, **the same column has different contents in the two modalities**: in the RNA object `rna_label` assigns 77 cells to ACH-000748 and 33 to ACH-000570; in the ATAC object the same `rna_label` assigns 653 and 423 to those IDs. For a properly paired multiome object a per-cell field must be identical whichever modality's `.obs` you read. ACH-000748 resolves (live Cellosaurus lookup) to SJSA-1, osteosarcoma — i.e. the discrepancy concentrates on SJSA1 and YKG1, which have 773 and 531 cells by ATAC but only 77 and 33 by RNA label.
- Both self-check columns (`may_have_wrong_cell_line_label_based_on_rna_cluster` / `..._based_on_atac`) report "no" for all 5,814 cells. Given the above, **that detector is uninformative — do not treat it as a clean bill of health.**
- Practical consequence: use `atac_label` / `cell_line_name` as ground truth; treat `rna_label` as unusable.

### Problem 2 — cross-modal cluster agreement is implausibly low (medium confidence that it's a real defect)
RNA–ATAC cluster ARI is **0.190**, yet each modality recovers the same 8-line ground truth well on its own (RNA ARI 0.767, ATAC ARI 0.906). Two clusterings that each track the same labeling at ~0.8–0.9 should agree with each other far better than 0.19. Part of this is benign over-clustering (14 RNA vs 10 ATAC clusters for 8 lines; ARI penalizes splitting), but splitting alone doesn't plausibly get you to 0.19. Combined with Problem 1, I read this as a partial cell-barcode/label alignment issue affecting a subset of cells rather than a global shuffle — the ESR1 and MDM2 cross-modal checks rule out wholesale scrambling.

### Caveats (not defects)
- **10.6% scrublet-called doublets appear to still be in the object.** In a pooled design these are inter-line hybrids and can generate spurious "intermediate" clusters — a plausible contributor to 14 RNA clusters and to the depressed cross-modal ARI. Filter before any clustering-dependent claim.
- **A-673 has only 164 cells** and spans 3 batches (b1/b2/b3) across 26 sequencing samples — underpowered for per-line conclusions.
- NKX2-1 and SOX2 were *not* significant markers of any cluster. That's not evidence of a problem: with two lung lines present, a shared lineage gene loses cluster specificity by construction.

## Evidence
| Claim | Source | Confidence |
|---|---|---|
| Depth/mito/ATAC QC numbers above | `get_qc_summary` | High |
| 8 lines + names/counts; no condition axis | `check_for_identity_columns`, `check_for_condition_groups` | High |
| ACH-000416 = NCI-H838 (lung adeno), ACH-000748 = SJSA-1 (osteosarcoma) | `resolve_depmap_id` (live Cellosaurus) | High |
| `rna_label` inconsistent between modalities (77 vs 653; 33 vs 423) and has ~60 spurious IDs | `check_for_identity_columns` | High |
| Mislabel-flag columns say "no" for all 5,814 cells despite the above | `check_for_identity_columns` | High |
| Cross-modal ARI 0.190 vs RNA 0.767 / ATAC 0.906 vs truth = anomalous | `get_qc_summary` + reasoning | Medium |
| Pairing not globally scrambled | `cross_modal_marker_check` ESR1 (cluster 4→4, confirmed), MDM2 (1→1, confirmed) | Medium-high |
| MDM2 amplification is characteristic of SJSA-1 | Background knowledge, not a tool result | Medium |

---

## 5. Novel findings, adversarial judging, and limitations
(Some findings omitted due to private dataset)

### Finding (confidence: high)

GRHL2 — not FOXA1, GATA3 or ESR1 — is the transcription factor whose own RNA best predicts its own motif's chromVAR accessibility in this dataset, by a ~3.5-fold margin, and GRHL2 is simultaneously a strong T-47D-cluster marker confirmed in both modalities. This nominates GRHL2 (a PR co-regulator at distal enhancers) rather than the canonical luminal pioneers as the dominant accessibility-tracking factor in this pooled panel.

**Evidence:** tf_motif_correlation: GRHL2 RNA vs MA1105.3.GRHL2 deviation Spearman rho = 0.373, p = 4.6e-191 — versus FOXA1 0.108 (p=2.0e-16, established), ESR1 0.082 (p=3.9e-10), GATA3 -0.079 (p=2.0e-09, established), TFAP2C 0.054 (p=4.4e-05), SPDEF 0.038 (p=3.9e-03), PGR 0.030 (p=0.021), XBP1 -0.016 (p=0.21, n.s.), ELF3 0.003 (p=0.84, n.s.), KLF5 -0.040 (p=2.5e-03). Other epithelial-restricted TFs (ELF3, KLF5, SPDEF) are near zero, so the effect is not a generic 'epithelial TF has high dynamic range in a pooled panel' artifact. top_cluster_markers(4): GRHL2 logFC 3.35, padj 2.2e-203; cross_modal_marker_check(GRHL2): RNA marker of cluster 4, matched ATAC cluster 4, gene-activity confirms. Dataset context: check_for_identity_columns shows 8 genotype-labeled lines, T-47D = ACH-000147, 697 cells; check_for_condition_groups: control-only. Literature: PMID 41843622 (abstract read) reports GRHL2 interacts with PR and is co-recruited with PR to distal enhancers in hormone-responsive breast cancer cells — consistent with, but not equal to, this accessibility-tracking claim.

**Judger verdict: struck_down**

- Likely artifact: True -- The rho is reproducible (GRHL2 0.373, p=4.6e-191) but is a cross-cell-line identity statistic, not a within-cell-type regulatory readout. check_for_identity_columns shows 8 genotype-labeled lines across 5 lineages with T-47D contributing only 697/5814 cells, so ~88% of cells driving the GRHL2 correlation are non-breast; check_for_condition_groups confirms control-only. Two unexcluded boring explanations: (1) prevalence-capped dynamic range - ESR1/PGR/GATA3/FOXA1 are essentially confined to the single 697-cell line (top_cluster_markers(4): ESR1 logFC 5.01, PGR 5.32, GATA3 4.73) whereas GRHL2's lower logFC 3.35 indicates expression shared beyond that line; a Spearman correlation against a near-binary predictor is structurally bounded by the 'on'-group prevalence (background statistical knowledge), giving a mechanical multi-fold advantage with no biological difference. (2) Motif-family degeneracy, not GRHL2 specialness - the cited controls fail because ELF3 (reproduced rho 0.003, p=0.84) and KLF5 (-0.040) have degenerate ETS/GC-box motifs shared with ubiquitously expressed family members, and GATA3's NEGATIVE rho (-0.079) shows GATA motif deviation is driven by other GATA factors in non-breast lines; the GRHL motif uniquely lacks a ubiquitously expressed family surrogate here (GRHL1 rho 0.062; GRHL3 has no motif in this dataset). Critically, the claimed ~3.5-fold margin collapses once other lines' lineage TFs are tested, which the original evidence omitted: PAX8 rho = 0.214 (p=4.4e-61, ovarian OVTOKO, family-unique motif) and RUNX2 = 0.129, so the true margin is ~1.7x and the generic pattern 'lineage-restricted TF + family-unique motif => high rho' reproduces in unrelated lineages (also TEAD1 0.088, POU3F2 0.096, TFAP2C 0.054, SOX9 -0.044, FLI1 -0.051, TP63 -0.006). The cross-modal leg is true but non-discriminating: cross_modal_marker_check confirms GRHL2 (RNA cluster 4 / ATAC cluster 4), but ESR1 and CDH1 confirm identically and top_gene_activity_markers(4) lists FOXA1 (1.78) and GATA3 (1.89) alongside GRHL2 (1.93), so the canonical pioneers pass the same test equally well. Data quality is not the issue (FRiP 0.62, TSS enrichment 14.6, ATAC-vs-truth ARI 0.906); the inferential design is.
- Already known: True -- Abstracts actually read, not just titles. PMID 29867222 (Nat Genet 2018) causally establishes that Grainy head binding sites determine epithelial enhancer accessibility, that Grh loss/ectopic expression causes loss/gain of DNA accessibility, that human GRHL1/GRHL2/GRHL3 function similarly, and concludes Grh binding is 'necessary and sufficient for the opening of epithelial enhancers' - a tight GRHL2-expression-to-GRHL2-motif-accessibility coupling is the direct predicted consequence of this established mechanism. PMID 32974388 (review) states explicitly that GRHL factors act as pioneer factors establishing a cell-type-specific accessible chromatin landscape exclusive to epithelial transcription. The 'rather than the canonical luminal pioneers' framing is also not new: PMID 31644911 already designates GRHL2 a lineage-determining factor collaborating with FOXA1 in ER+/endocrine-resistant breast cancer, and PMID 36036613 shows GRHL2 is pre-bound at chromatin and required for maximal ER recruitment at enhancers. Thus GRHL2 being the factor whose expression best tracks its own motif accessibility is an expected restatement of well-established pioneer-factor biology, not a novel nomination.

### Finding (confidence: medium)

Both GATA-family factors assayed here show NEGATIVE self-motif tracking, and the stronger of the two is TRPS1 — the atypical GATA repressor, which is the single highest-ranked RNA marker of the T-47D cluster (ranked above ESR1, PGR and GATA3) and is cross-modally confirmed. This offers a concrete, mechanistic candidate explanation for the otherwise anomalous negative GATA3 RNA-vs-GATA3-motif correlation: GATA-element accessibility in this luminal line is co-occupied by a NuRD-recruiting repressor rather than being a pure GATA3-activation readout.

**Evidence:** tf_motif_correlation: TRPS1 RNA vs MA1970.2.TRPS1 deviation Spearman rho = -0.148, p = 7.4e-30 (more strongly negative than the already-established GATA3 rho = -0.079, p = 2.0e-09). top_cluster_markers(4): TRPS1 is the #1-ranked marker of the T-47D RNA cluster, logFC 4.15, padj 6.9e-275, above ESR1 (5.01, 8.3e-245), PGR (5.32, 6.3e-242) and GATA3 (4.73, 4.8e-177) by DE score. cross_modal_marker_check(TRPS1): RNA marker of cluster 4, matched ATAC cluster 4, gene activity confirms. Literature (abstracts read): PMID 30563971 shows TRPS1 is an atypical GATA factor that recognizes GATA elements and represses transcription by recruiting CHD4/NuRD(MTA2), including enhancer decommissioning at TP63; PMID 19759027 confirms TRPS1 binds a GATA consensus site directly to repress a target promoter. Caveat: the correlations are computed across all 5814 cells of an 8-line pool, so cross-line variance contributes; the tools available cannot restrict the correlation to T-47D cells alone.

**Judger verdict: struck_down**

- Likely artifact: True -- The stated premise is factually wrong in this dataset, and the inference is confounded by the pooled design.

(1) PREMISE FALSE. The claim says "both GATA-family factors assayed here show NEGATIVE self-motif tracking." I found five assayable GATA-family factors, and the majority are POSITIVE: TRPS1 -0.148 (p=7.4e-30), GATA3 -0.079 (p=2.0e-09), but GATA2 +0.134 (p=1.2e-24), GATA6 +0.139 (p=2.5e-26), GATA4 +0.045 (p=6.4e-04) (tf_motif_correlation). GATA1/GATA5 are absent from the RNA var_names. There is no GATA-family-wide negative self-motif tracking.

(2) MECHANISM FALSIFIED BY (1). GATA2/3/4/6 and TRPS1 all read essentially the same WGATAA consensus (background knowledge), so their chromVAR deviation scores are largely redundant measurements of the same accessibility feature. If GATA-element accessibility were globally confounded by a NuRD-recruiting co-occupying repressor, every GATA-motif deviation would behave the same way. Instead the sign flips according to which TF's RNA it is — which is the signature of a between-cell-line contrast, not of chromatin co-occupancy.

(3) POOLED-LINE CONFOUND IS THE WHOLE EFFECT. check_for_identity_columns shows an 8-line pool (NCI-H838 1626, HCC-44 817, SJSA1 773, T-47D 697, OVTOKO 627, LN-229 579, YKG1 531, A-673 164; lineages Lung/CNS/Bone/Breast/Ovary). TRPS1 RNA is effectively a T-47D indicator (top marker of RNA cluster 4). So rho(TRPS1 RNA, GATA-motif deviation) across all 5814 cells is little more than "GATA-motif accessibility in the 12% breast cells vs the 88% non-breast majority." The negative sign is fully explained by GATA-motif deviation being relatively higher in the non-breast lines — consistent with the GATA6-positive lung lines (GATA6 rho +0.139), which dominate the pool. The submission concedes it cannot restrict to T-47D; that concession is not a caveat, it is the entire result.

(4) EFFECT SIZE IS AT THE NOISE FLOOR. rho=-0.148 is ~2% of variance, inside the same |rho| 0.04-0.15 band as CTCF (+0.066), ESR1 (+0.082), FOXA1 (+0.108), GATA4 (+0.045). Decisive internal control: GRHL2 — also a T-47D cluster-4 marker (logFC 3.35) in the same pool, same cluster, same design — gives +0.373 (p=4.6e-191), 2.5x larger and positive. So the pooled design does NOT force weak/negative self-motif correlations; a genuinely self-tracking TF produces a much stronger positive one. TRPS1's value does not stand out from noise.

(5) THE CORROBORATION IS A NON-SEQUITUR. I reproduced the marker evidence exactly (top_cluster_markers(4): TRPS1 first by DE score, logFC 4.15, padj 6.9e-275; cross_modal_marker_check(TRPS1): is_rna_marker true, rna_cluster 4, matched_atac_cluster 4, gene_activity_confirms true). It is real, but it only establishes that TRPS1 is breast-cell-type-specific — it carries no information about the sign of a pooled self-motif correlation, so it cannot corroborate the mechanistic claim. Note also the "ranked above ESR1, PGR and GATA3" framing is a ranking-metric artifact: TRPS1's logFC (4.15) is LOWER than ESR1 (5.01), PGR (5.32) and GATA3 (4.73); it leads only on the DE z-score, which rewards low within-cluster variance.

(6) Minor: get_qc_summary reports 10.6% doublets in a multiplexed 8-line pool, which adds cross-line RNA/ATAC mixing that further degrades pooled per-cell correlations. Data quality is otherwise good (FRiP 0.62, TSS 14.6, ARI 0.725), so QC is not the problem — the inference is.
- Already known: True -- Every biological component of the proposal is already published, and the strongest paper reports it in precisely the relevant system with far better methods.

PMID 38377146 (PLoS Genetics 2024), abstract read: opens by calling TRPS1 "the repressive GATA-family transcription factor (TRPS1)," notes "luminal breast cancer cell lines are particularly sensitive to TRPS1 knockout," and reports via an inducible degron in a luminal breast cancer line that "TRPS1 directly regulates chromatin structure," redistributing ER across the genome. That is the proposed finding — a repressive GATA-family factor shaping chromatin/GATA-element accessibility in a luminal breast line — already demonstrated with acute degradation and direct chromatin readouts, which is vastly stronger evidence than a rho of -0.15.

PMID 30563971 (Oncogenesis 2018), abstract read (the submission's own citation): TRPS1 is an atypical GATA factor that "guides the machinery to specific target sites by recognizing GATA elements" and recruits CHD4/NuRD(MTA2) to repress, including enhancer decommissioning at TP63. The submission cites this as background yet the proposed "mechanistic candidate" adds nothing to it.

PMID 38647255 (Am J Surg Pathol 2024, 19,201 tumors) and PMID 39243111 (Diagn Pathol 2024), abstracts read: TRPS1 is a highly sensitive, routinely used breast-cancer IHC marker, "a nuclear protein highly expressed in breast epithelial cells," with TRPS1+GATA3 co-positivity in 47.4-100% of breast cancers. So "TRPS1 is the top-ranked marker of the breast cluster, above GATA3" is standard diagnostic pathology, not a discovery.

What would be genuinely new is a demonstration that TRPS1 occupancy makes GATA-motif accessibility anti-correlate with GATA3 activity WITHIN luminal cells. The submission does not show that, and the available tools cannot: the correlation cannot be restricted to T-47D, and my GATA2/GATA4/GATA6 results argue against it anyway.

### Finding (confidence: medium)

The T-47D cluster's identity in this dataset is defined at least as strongly by a cytokine-receptor/JAK-STAT hormone axis (PRLR, GHR, ERBB4) as by the classic steroid-receptor axis: PRLR has the largest log-fold-change of any marker of the cluster, exceeding both PGR and ESR1, is cross-modally confirmed, and JAK-STAT receptor signaling comes out as a top GO enrichment of the marker set essentially tied with 'response to estrogen'.

**Evidence:** top_cluster_markers(4, n=30): PRLR logFC 6.46, padj 1.7e-273 — the largest logFC in the top-30 set, above PGR (5.32) and ESR1 (5.01); GHR logFC 4.44, padj 1.1e-190; ERBB4 logFC 3.73, padj 1.4e-226. cross_modal_marker_check(PRLR): RNA marker of cluster 4, matched ATAC cluster 4, gene activity confirms (so the receptor locus is also independently more accessible, not just more transcribed). enrich_gene_set on the top-30 markers: 'Positive Regulation Of Receptor Signaling Pathway Via JAK-STAT (GO:0046427)' adj p = 3.8e-03 (GHR, ERBB4, PRLR), ranked alongside 'Response To Estrogen (GO:0043627)' adj p = 3.8e-03 (KRT19, GATA3, ESR1). Honest caveat: prolactin responsiveness of this line is established background knowledge (e.g. PMID 23410749, title-level only), so what is new here is the quantitative ranking (PRLR > PGR > ESR1 by effect size), the independent ATAC gene-activity confirmation, and the module-level co-enrichment with GHR/ERBB4 — not the existence of PRLR expression itself.

**Judger verdict: struck_down**

- Likely artifact: True -- The underlying numbers replicate exactly, but the INTERPRETATION rests on three invalid inferential steps.

(1) logFC is not an "identity-defining strength" metric in this design. check_for_identity_columns shows this is a pool of 8 genotype-confirmed cell lines (T-47D n=697; the other 7 are lung NCI-H838/HCC-44, osteosarcoma SJSA1, ovarian OVTOKO, glioma LN-229/YKG1, Ewing A-673). So logFC for cluster 4 = T-47D vs. a mean over 7 unrelated non-breast lineages, in all of which PRLR, PGR and ESR1 are ~0. With a near-zero denominator the ordering collapses to relative transcript abundance in T-47D plus pseudocount/dropout behaviour, and it is entirely contingent on an arbitrary comparison set (replace the 7 lines with other ER+ breast lines and PRLR's logFC would collapse). Notably the statistic the list is actually RANKED by tells the opposite story: TRPS1 is rank 1, and ESR1 (padj 8.3e-245) and PGR (6.3e-242) both beat ERBB4 (1.4e-226) and GHR (1.1e-190).

(2) The cross-modal confirmation is non-discriminating. I ran cross_modal_marker_check myself on all three: PRLR, ESR1 and PGR are ALL is_rna_marker=true, matched_atac_cluster=4, gene_activity_confirms=true. Citing PRLR's ATAC confirmation as evidence that the cytokine axis rivals the steroid axis is invalid — the steroid receptors pass the identical test.

(3) The GO "tie" is a Benjamini-Hochberg artifact. My own enrich_gene_set rerun on the same 30 genes gives Response To Estrogen nominal p=1.77e-05 and JAK-STAT nominal p=2.29e-05; they share adj p=0.00377 only because BH assigns tied adjusted values to adjacent ranks. Estrogen is nominally the stronger term. The JAK-STAT hit is also a 3-gene annotation tautology (PRLR and GHR are class-I cytokine receptors by definition, so the term is guaranteed once they are in the list), whereas the ER/luminal program is far more broadly represented across the marker set (ESR1, PGR, GREB1, GATA3, TRPS1, AFF3, KRT19, and at n=60 also STC2, CA12, RERG, XBP1, INPP4B — canonical estrogen-induced/luminal genes, background knowledge).

(4) The one independent functional test I could run contradicts the claim. tf_motif_correlation: STAT5A rho=-0.024, p=0.065 (non-significant); STAT5B rho=-0.079, p=1.4e-09 (significantly NEGATIVE); ESR1 rho=+0.082, p=3.9e-10 (significantly positive). There is no positive evidence of STAT5 regulatory activity, while the ER axis is the one with supportive motif evidence. I weight this as supporting rather than decisive, because the effect sizes are tiny and GATA3 is also negative (rho=-0.079, p=2.0e-09) despite being a bona fide luminal TF — the motif tool is noisy in a pooled multi-lineage dataset. Biologically this is also the expected "receptor present but unstimulated" case: PRLR/GHR/ERBB4 are ligand-dependent receptors and standard culture medium supplies no prolactin or GH (background knowledge), so receptor mRNA/accessibility is not evidence of an active JAK-STAT axis.

Things that do survive scrutiny and are NOT artifacts: cluster 4 really is T-47D (genotype-confirmed metadata field, 697 cells — no small-sample problem; ATAC-vs-truth ARI 0.906 per get_qc_summary), QC is good (median 4258 genes/cell, FRiP 0.62, TSS enrichment 14.6), there is no condition axis to confound (check_for_condition_groups: control-only), and I verified by extending to n=60 that PRLR's logFC of 6.46 is indeed the largest in the top 60. So the measurements are sound; it is the ranking-based interpretation that does not survive.
- Already known: True -- (not provided)


### Limitations

- "Faults detected"/"diagnosis matches" use heuristic free-text classifiers on the agent's open-ended answer, not exact ground-truth string matching.
- Known-biology checklist items are generated fresh each run via literature RAG, not scored against a fixed pre-written ground-truth file -- recall/precision against a fixed checklist is a different, complementary evaluation this report doesn't repeat.
- Gene activity is a noisier, indirect accessibility proxy than direct RNA counts; cross-modal disagreement on a real marker is expected, not necessarily a data-quality issue.
- This report reflects a single run on one model; consistency across repeated runs (or across models) is a separate axis this report doesn't cover.
- ATAC downsampling and doublet injection (used for the public dataset) could not be reused as-is here: this dataset has no raw fragments file (downsampling needs one) and RNA `.X` has no raw counts layer (doublet injection needs one) -- a real format constraint, not a design choice. The fault-injection section uses cell-line-label-swap, mixed-samples, and shuffled-RNA-ATAC-pairing instead.
- This dataset has no drug/treatment condition axis (checked by column name via `check_for_condition_groups`, not assumed) -- every cell is a control. The pipeline supports condition-level analysis (per-arm QC via `condition_group_qc`, condition-specific literature RAG) for a future dataset that does have one; it's simply not exercised here.
- The negative-control check was NOT run for this report. See the public report's own negative-control section for what this check looks like when it does run.


---

## Cost breakdown

- loader_decision: $0.0356
- checklist_generation: $10.5883
- novelty_proposal: $6.2832
- judging: $12.0344
- fault_injection: $13.4132
- **Total: $42.3547**
